



I, Karen Lee, hereby certify that I am competent to translate from Chinese to English and that the attached translation is, to the best of my knowledge and belief, a true and accurate translation of the following document from Chinese to English.

Excerpt from Ex. 2021 - Bio-Thera Solutions, Ltd. 2024 Annual Report (Chinese)

A handwritten signature in black ink, appearing to read 'K Lee'.

Karen Lee

Sworn to before me this
June 15, 2026

A handwritten signature in black ink, appearing to be a stylized 'M' followed by a flourish.

Signature, Notary Public

Mikhail E. Lezhnev
Notary Public ID No. 02LE0003393
State of New York Qualified in Kings County
Commission Expires on March 22, 2027

Stamp, Notary Public

LANGUAGE AND TECHNOLOGY SOLUTIONS FOR GLOBAL BUSINESS

1250 BROADWAY, 7TH FLOOR, NEW YORK, NY 10001 | T 212.689.5555 | F 212.689.1059 | WWW.TRANSPERFECT.COM

OFFICES IN 92 CITIES WORLDWIDE

Accord BioPharma, Inc.
Exhibit 1099
Accord v. Janssen
IPR2026-00256, -00257, -00258, -00259
Ex. 1099-001

Company Code: 688177

Company Abbreviation: Bio-Thera

Bio-Thera Solutions, Ltd.

2024 Annual Report



Table of Contents

Section I	Definitions	5
Section II	Company Profile and Key Financial Indicators	8
Section III	Management Discussion and Analysis.....	13
Section IV	Corporate Governance.....	63
Section V	Environmental, Social Responsibility and Other Corporate Governance Matters	79
Section VI	Significant Matters.....	92
Section VII	Changes in Shares and Shareholder Information	146
Section VIII	Preferred Share Information.....	153
Section IX	Bond Information.....	153
Section X	Financial Report.....	154

Index of Documents Available for Inspection	Financial report signed and sealed by the Company's legal representative, the person in charge of accounting affairs, and the head of the accounting department.
	Original audit report bearing the seal of the accounting firm and the signatures and seals of the certified public accountants.
	Original copies of all Company documents and announcements publicly disclosed during the reporting period.

Section VII Changes in shares and shareholder information

I. Changes in share capital

(I) Table of changes in shares

1. Table of changes in shares

During the reporting period, there was no change in the total number of shares or the share capital structure of the Company.

2. Explanation of changes in shares

☐ Applicable ☒ Not applicable

3. Impact of changes in shares on financial indicators such as earnings per share and net assets per share for the most recent year and most recent period (if any)

☐ Applicable ☒ Not applicable

4. Other matters deemed necessary by the Company or required to be disclosed by securities regulatory authorities

☐ Applicable ☒ Not applicable

(II) Changes in restricted shares

☐ Applicable ☒ Not applicable

II. Securities issuance and listing

(I) Securities issuance during the reporting period

☐ Applicable ☒ Not applicable

Explanation of securities issuance during the reporting period (for bonds with different interest rates during their term, please describe separately):

☐ Applicable ☒ Not applicable

(II) Changes in the total number of shares and shareholder structure of the Company, and changes in the Company's asset and liability structure

☐ Applicable ☒ Not applicable

III. Shareholders and actual controllers

(I) Total number of shareholders

Total number of ordinary shareholders as of the end of the reporting period (accounts)	8,387
Total number of ordinary shareholders as of the end of the month preceding the disclosure date of the annual report (accounts)	8,526
Total number of preferred shareholders with restored voting rights as of the end of the reporting period (accounts)	0
Total number of preferred shareholders with restored voting rights as of the end of the month preceding the disclosure date of the annual report (accounts)	0
Total number of shareholders holding shares with special voting rights as of the end of the reporting period (accounts)	0
Total number of shareholders holding shares with special voting rights as of the end of the month preceding the disclosure date of the annual report (accounts)	0

Number of depositary receipt holders

☐ Applicable ☒ Not applicable

(II) Shareholdings of the top ten shareholders and top ten circulating shareholders (or shareholders without selling restrictions) as of the end of the reporting period

Unit: shares

Shareholdings of the top ten shareholders (excluding shares lent through securities lending and refinancing)							
Name of shareholder (Full name)	Increase/ decrease during the reporting period	Number of shares held at the end of the period	Percen tage (%)	Number of shares subject to selling restriction s held	Pledged, marked, or frozen shares		Nature of shareholder
					Share status	Quan tity	
Guangzhou Qixi Group Co., Ltd.	0	159,990,270	38.64	0	None	0	Domestic non-state-owned legal person
Therabio International Limited	0	47,177,729	11.39	0	None	0	Foreign legal person
Guangzhou Qiao Xing Investment Partnership (Limited Partnership)	0	23,173,326	5.60	0	None	0	Domestic non-state-owned legal person
Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd. – Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership)	0	21,333,332	5.15	0	None	0	Domestic non-state-owned legal person
Xinyu Qiheng Management Consulting Partnership (Limited Partnership)	-170,000	19,991,839	4.83	0	None	0	Domestic non-state-owned legal person
Guangzhou Shengyu Investment Partnership (Limited Partnership)	0	16,000,000	3.86	0	None	0	Domestic non-state-owned legal person
Yi Liangyu	0	11,760,002	2.84	0	None	0	Domestic natural person
Guangzhou Fanwanhu Investment Partnership (Limited Partnership)	1,400	7,424,586	1.79	0	None	0	Domestic non-state-owned legal person
SHENGFENG LI	0	6,517,332	1.57	0	None	0	Foreign natural person
Huitianze Investment Co., Ltd.	0	4,560,931	1.10	0	None	0	Domestic non-state-owned legal person
Shareholdings of the top ten shareholders without selling restrictions (excluding shares lent through securities lending and refinancing)							
Name of shareholder		Number of unrestricted circulating shares held	Class and quantity of shares				
			Class	Quantity			
Guangzhou Qixi Group Co., Ltd.		159,990,270	RMB ordinary shares		159,990,270		
Therabio International Limited		47,177,729	RMB ordinary shares		47,177,729		
Guangzhou Qiao Xing Investment Partnership (Limited Partnership)		23,173,326	RMB ordinary shares		23,173,326		
Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd. – Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership)		21,333,332	RMB ordinary shares		21,333,332		
Xinyu Qiheng Management Consulting Partnership (Limited Partnership)		19,991,839	RMB ordinary shares		19,991,839		
Guangzhou Shengyu Investment Partnership (Limited Partnership)		16,000,000	RMB ordinary shares		16,000,000		
Yi Liangyu		11,760,002	RMB ordinary shares		11,760,002		
Guangzhou Fanwanhu Investment Partnership (Limited Partnership)		7,424,586	RMB ordinary shares		7,424,586		
SHENGFENG LI		6,517,332	RMB ordinary shares		6,517,332		
Huitianze Investment Co., Ltd.		4,560,931	RMB ordinary shares		4,560,931		
Explanation of repurchase special account among the top	Not applicable						

ten shareholders	
Explanation of proxy voting rights, entrusted voting rights, and waived voting rights of the above shareholders	Not applicable
Explanation of related-party relationships or persons acting in concert among the above shareholders	1.Related-party relationships: (1) Guangzhou Qixi Group Co., Ltd. is ultimately controlled by the actual controllers Yi Xianzhong, Guan Yuchan, and Yi Liangyu; (2) The general partner and executive partner of Guangzhou Qiao Xing Investment Partnership (Limited Partnership) is Guan Yuchan and is ultimately controlled by Guan Yuchan; (3) Guangzhou Qixi Group Co., Ltd. holds a 74% limited partnership interest in Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership), and Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd., in which Guan Yuchan holds a 55% interest, serves as the general partner of Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership); (4) The general partner and executive partner of Guangzhou Shengyu Investment Partnership (Limited Partnership) is Yi Xianzhong and is ultimately controlled by Yi Xianzhong; (5) The general partner and executive partner of Hengqin CAS Zhuochuang Equity Investment Fund Partnership (Limited Partnership) is Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd., in which Guan Yuchan holds a 55% interest, and is ultimately controlled by Guan Yuchan; (6) Therabio International Limited is a company 100% owned by LI SHENGFENG and his wife and children; (7) Guangzhou Fanwanhu Investment Partnership (Limited Partnership) is a limited partnership in which LI SHENGFENG and his children contribute 100% of the capital, and LI SHENGFENG serves as the general partner and executive partner; (8) The general partner and executive partner of Xinyu Qiheng Management Consulting Partnership (Limited Partnership) is Jifu Venture Capital; (9) The controlling shareholder of Huitianze Investment Co., Ltd., Dong Zhengqing, is also the largest shareholder of Jifu Venture Capital. 2.Persons acting in concert: (1) Controlling shareholder Qixi Group and its persons acting in concert: Guangzhou Qiao Xing Investment Partnership (Limited Partnership), Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership), Guangzhou Shengyu Investment Partnership (Limited Partnership), Hengqin CAS Zhuochuang Equity Investment Fund Partnership (Limited Partnership), Yi Liangyu, Yi Xianzhong, and Guan Yuchan; (2) Therabio International Limited and its persons acting in concert: SHENGFENG LI and Guangzhou Fanwanhu Investment Partnership (Limited Partnership); (3) Xinyu Qiheng Management Consulting Partnership (Limited Partnership) and its persons acting in concert: Huitianze Investment Co., Ltd.
Explanation of preferred shareholders with restored voting rights and the number of shares held	Not applicable

Share lending through securities lending and refinancing by shareholders holding more than 5% of shares, the top ten shareholders, and the top ten shareholders of unrestricted circulating shares

√ Applicable □ Not applicable

Unit: shares

Share lending through securities lending and refinancing by shareholders holding more than 5% of shares, the top ten shareholders, and the top ten shareholders of unrestricted circulating shares								
Name of shareholder (full name)	Shares held in ordinary accounts and credit accounts at the beginning of the period		Shares lent through securities lending and refinancing and not yet returned at the beginning of the period		Shares held in ordinary accounts and credit accounts at the end of the period		Shares lent through securities lending and refinancing and not yet returned at the end of the period	
	Total number	Percentage (%)	Total number	Percentage (%)	Total number	Percentage (%)	Total number	Percentage (%)
Guangzhou Fanwanhu Investment Partnership (Limited Partnership)	7,423,186	1.79	1,400	0.00	7,424,586	1.79	0	0.00